The approved ALS therapy Radicava may cause serious unexpected side effects, such as liver problems and blood clots, per U.S.

Coya Therapeutics, Inc.’s COYA share price has surged by 12.31%, which has investors questioning if this is right time to ...

A special art tour program at the Virginia Museum of Fine Arts is bringing light and connection to people living with ALS and ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

Clene’s cash and cash equivalents totaled $9.8 million as of March 31, 2025, compared to $12.2 million as of December 31, 2024. Clene expects that its resources as of March 31, 2025, will be ...

The third patient of Elon Musk's brain computer interface company Neuralink is using the billionaire's foul-mouthed AI ...

Smith is the first non-verbal individual and only the third person globally to receive a Neuralink Brain-Chip Interface (BCI) implant.

A groundbreaking achievement in brain-computer interface technology: an ALS patient uses a Neuralink implant to edit and narrate a YouTube video.

Alchemab Therapeutics, whose labs are in Cambridge UK, stands to scoop $415 million from Eli Lilly and Company following a ...

VectorY Therapeutics, a biotech company developing disease-modifying vectorized antibody therapies for the treatment of ...

Jesse Robertson tells PEOPLE how after his mom Donna died, he tried to print a copy of his favorite photo of her.

Alchemab Therapeutics enters $415 million licensing agreement with Eli Lilly for ATLX-1282: Cambridge, UK Wednesday, May 7, 2025, 12:00 Hrs [IST] Alchemab Therapeutics (Alchemab), ...